Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To date, there are no reliable diagnostic blood markers of adult vasculitis. To date, the diagnosis of vasculitis is based on invasive procedure, biopsy of affected tissues potentially at risk of complication . In addition, there are no reliable biomarkers to predict the evolution of vasculitis (relapse, refractory form ...) necessary for the management of patients (type of treatment, duration ..)
Prospective study, monocentric (CHU de Tours), non-interventional, aimed at finding diagnostic and prognostic biomarkers (both metabolomic and immunologic) in adult vasculitis patients.
Specimen will be collected at diagnosis, month 1, month 3, and month12 and at the time of a possible relapse. 14 ml of additional blood during a blood puncture made for routine care will be collected at each visit as well as clinical data.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients with vascularitis | Two additional 7ml EDTA tubes of blood are taken from the same blood puncture as during routine follow-up at several points in the follow-up |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sampling | Other | 4 blood sampling per patient and an additional one in case of relapse |
|
| Measure | Description | Time Frame |
|---|---|---|
| cytokine/chemokine/metabolite concentrations | Analysis by méthod Luminex | Baseline |
| cytokine/chemokine/metabolite concentrations | Analysis by méthod Luminex | Month 1 |
| cytokine/chemokine/metabolite concentrations | Analysis by méthod Luminex | Month 3 |
| cytokine/chemokine/metabolite concentrations | Analysis by méthod Luminex | Month 12 |
| cytokine/chemokine/metabolite concentrations | Analysis by méthod Luminex | date of relapse assessed up to 12 months |
| percentage of different non-conventional T cell populations | study by flow cytometry | Baseline |
| percentage of different non-conventional T cell populations | study by flow cytometry | Month 1 |
| percentage of different non-conventional T cell populations | study by flow cytometry | Month 3 |
| percentage of different non-conventional T cell populations |
| Measure | Description | Time Frame |
|---|---|---|
| cytokine/chemokine/metabolite concentrations | identify a metabolomic blood profile for the prognosis of vasculitis | baseline |
| cytokine/chemokine/metabolite concentrations | identify a metabolomic blood profile for the prognosis of vasculitis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with vascularitis
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexandra Audemard verger | Contact | 02 47 47 37 15 | +33 | alexandra.audemardverger@univ-tours.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University hospital | Recruiting | Tours | 37044 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014657 | Vasculitis |
| D004194 | Disease |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Sampling at diagnosis, at M1, M3, M12 and at the time of a possible relapse: 14 ml of additional blood during a blood puncture for routine care will be collected at each visit together with clinical data.
study by flow cytometry |
| Month 12 |
| percentage of different non-conventional T cell populations | study by flow cytometry | date of relapse assessed up to 12 months |
| Month 1 |
| cytokine/chemokine/metabolite concentrations | identify a metabolomic blood profile for the prognosis of vasculitis | Month 3 |
| cytokine/chemokine/metabolite concentrations | identify a metabolomic blood profile for the prognosis of vasculitis | Month 12 |
| cytokine/chemokine/metabolite concentrations | identify a metabolomic blood profile for the prognosis of vasculitis | date of relapse assessed up to 12 months |
| percentage of different non-conventional T cell populations | identify an immunological blood profile for the prognosis of vasculitis | baseline |
| percentage of different non-conventional T cell populations | identify an immunological blood profile for the prognosis of vasculitis | Month 1 |
| percentage of different non-conventional T cell populations | identify an immunological blood profile for the prognosis of vasculitis | Month 3 |
| percentage of different non-conventional T cell populations | identify an immunological blood profile for the prognosis of vasculitis | Month 12 |
| percentage of different non-conventional T cell populations | identify an immunological blood profile for the prognosis of vasculitis | date of relapse assessed up to 12 months |
| metabolomic pathway | Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | baseline |
| metabolomic pathway | Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | Month 1 |
| metabolomic pathway | Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | Month 3 |
| metabolomic pathway | Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | Month 12 |
| metabolomic pathway | Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | date of relapse assessed up to 12 months |
| immunological pathway | Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | baseline |
| immunological pathway | Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | Month 1 |
| immunological pathway | Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | Month 3 |
| immunological pathway | Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | Month 12 |
| immunological pathway | Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy. | date of relapse assessed up to 12 months |